TrialCompass TCL
Back to results
Phase 1, Phase 2RecruitingPriority 3 · Moderate priorityNCT06176027

Azacytidine Plus CAOLD Regimen in Relapsed/Refractory Peripheral T-Cell Lymphomas

ClinicalTrials.gov

Plain-language summary

This Phase 1, Phase 2 trial is testing Azacytidine plus CAOLD regimen for people whose T-cell lymphoma has come back or has not responded to previous treatment. The study starts with lower doses to find the safest effective dose before testing in more people. This trial does not currently list US sites.

Who can join (key eligibility)

  • Age 18 Years or older
  • Lymphoma came back or did not respond to prior treatment

Final eligibility is determined by the trial team. This list is a starting point only.

What's being tested

Azacytidine plus CAOLD regimen (DRUG): Patients were treated by Azacytidine(75 mg/m2 on days 1-7) plus CAOLD regimen (cyclophosphamide 400mg/m2 qd d1; cytarabine 30mg/m2 qd d1-d4; vindesine 2mg/m2 qd d1; pegaspargase 2500iu/m2 qd d2; dexamethasone 7.5mg/m2 qd d1-d5)

Drugs / treatments
Azacytidine plus CAOLD regimen
Treatment length
Ask the trial team for details
Visit frequency
Ask the trial team for details
TrialCompass — Clinical Trial Summary

Azacytidine Plus CAOLD Regimen in Relapsed/Refractory Peripheral T-Cell Lymphomas

NCT06176027

Phase: Phase 1, Phase 2 | Status: Recruiting | Priority: Medium

Plain-language summary

This Phase 1, Phase 2 trial is testing Azacytidine plus CAOLD regimen for people whose T-cell lymphoma has come back or has not responded to previous treatment. The study starts with lower doses to find the safest effective dose before testing in more people. This trial does not currently list US sites.

Who can join

  • Age 18 Years or older
  • Lymphoma came back or did not respond to prior treatment

What's being tested

Azacytidine plus CAOLD regimen (DRUG): Patients were treated by Azacytidine(75 mg/m2 on days 1-7) plus CAOLD regimen (cyclophosphamide 400mg/m2 qd d1; cytarabine 30mg/m2 qd d1-d4; vindesine 2mg/m2 qd d1; pegaspargase 2500iu/m2 qd d2; dexamethasone 7.5mg/m2 qd d1-d5)

Drugs / treatments: Azacytidine plus CAOLD regimen

Treatment length: Ask the trial team for details

Visit frequency: Ask the trial team for details

Trial design

Non-randomized, open-label

Enrollment target: 52 patients

Primary endpoint: Overall Response Rate (ORR)

Ages: 18 Years to —

Start date: 2024-10-01 | Est. completion: 2030-09-01

Locations

0 US sites · 1 total

Contact

Liren Qian, PhD | qlr2007@126.com | +861066957676

Sponsor: Navy General Hospital, Beijing (OTHER)

Tags

All T-cell lymphomas · Relapsed/Refractory

View on ClinicalTrials.gov

https://clinicaltrials.gov/study/NCT06176027

Prepared using TrialCompass (trialcompass.com) on June 19, 2026. For informational purposes only. Always discuss with your healthcare team.